Literature DB >> 33103943

Surgical Reintervention Rates after Invasive Treatment for Lower Urinary Tract Symptoms due to Benign Prostatic Syndrome: A Comparative Study of More than 43,000 Patients with Long-Term Followup.

Christian Gilfrich1, Matthias May1, Claus Fahlenbrach2, Christian Günster3, Elke Jeschke3, Gralf Popken4, Jens-Uwe Stolzenburg5, Lothar Weissbach6, Christoph von Zastrow7, Hanna Leicht3.   

Abstract

PURPOSE: No large-scale comparison of the 4 most established surgical approaches for lower urinary tract symptoms due to benign prostate obstruction in terms of long-term efficacy is available. We compared photoselective vaporization, laser enucleation and open simple prostatectomy to transurethral resection with regard to 5-year surgical reintervention rates.
MATERIALS AND METHODS: A total of 43,041 male patients with lower urinary tract symptoms who underwent transurethral resection (34,526), photoselective vaporization (3,050), laser enucleation (1,814) or open simple prostatectomy (3,651) between 2011 and 2013 were identified in pseudonymized claims and core data of the German local health care funds and followed for 5 years. Surgical reinterventions for lower urinary tract symptoms, urethral stricture or bladder neck contracture were evaluated. Surgical approach was related to reintervention risk using the Kaplan-Meier method and Cox proportional hazards models.
RESULTS: A total of 5,050 first reinterventions were performed within 5 years of primary surgery (Kaplan-Meier survival without reintervention: 87.5%, 95% CI 87.2%-87.8%). Photoselective vaporization carried an increased hazard of reintervention (HR 1.31, 95% CI 1.17-1.46, p <0.001) relative to transurethral resection, open simple prostatectomy carried a lower hazard (HR 0.43, 95% CI 0.37-0.50, p <0.001) and laser enucleation of the prostate did not differ significantly (HR 0.84, 95% CI 0.66-1.08, p=0.2). This pattern was more pronounced regarding reintervention for lower urinary tract symptom recurrence (photoselective vaporization: HR 1.52, 95% CI 1.35-1.72, p <0.001; laser enucleation of the prostate: HR 0.84, 95% CI 0.63-1.14, p=0.3; open simply prostatectomy: HR 0.38, 95% CI 0.31-0.46, p <0.001 relative to transurethral resection).
CONCLUSIONS: Five-year reintervention rates of transurethral resection and laser enucleation did not differ significantly, while photoselective vaporization had a substantially higher rate. Open simple prostatectomy remains superior to transurethral resection with respect to long-term efficacy.

Entities:  

Keywords:  laser therapy; prostatectomy; prostatic hyperplasia; transurethral resection of prostate; urethral stricture

Mesh:

Year:  2020        PMID: 33103943     DOI: 10.1097/JU.0000000000001463

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  High rates of re-intervention after photoselective vaporization of the prostate.

Authors:  Rebecca Tregunna
Journal:  Nat Rev Urol       Date:  2021-03       Impact factor: 14.432

2.  Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results.

Authors:  Kevin C Zorn; Mohamed Bidair; Andrew Trainer; Andrew Arther; Eugene Kramolowsky; Mihir Desai; Leo Doumanian; Dean Elterman; Ronald P Kaufman; James Lingeman; Amy Krambeck; Gregg Eure; Gopal Badlani; Mark Plante; Edward Uchio; Greg Gin; S Larry Goldenberg; Ryan Paterson; Alan So; Mitchell Humphreys; Claus Roehrborn; Steven Kaplan; Jay Motola; Naeem Bhojani
Journal:  BJUI Compass       Date:  2021-10-28

3.  Round Up.

Authors:  Santosh Kumar
Journal:  Indian J Urol       Date:  2021 Apr-Jun

4.  Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies.

Authors:  Dean Elterman; Peter Gilling; Claus Roehrborn; Neil Barber; Vincent Misrai; Kevin C Zorn; Naeem Bhojani; Alexis Te; Mitch Humphreys; Steven Kaplan; Mihir Desai; Thorsten Bach
Journal:  BMJ Surg Interv Health Technol       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.